|
Jun 25
|
Arbutus Reacquires Greater China Rights to Imdusiran and Announces Scientific Advisory Board with Late-Stage Clinical Focus
|
|
May 14
|
Arbutus Biopharma (ABUS) Reports Q1 Loss, Tops Revenue Estimates
|
|
May 14
|
Arbutus: Q1 Earnings Snapshot
|
|
May 14
|
Arbutus Reports First Quarter 2025 Financial Results and Provides Corporate Update
|
|
May 13
|
Is Editas Medicine (EDIT) Stock Outpacing Its Medical Peers This Year?
|
|
May 7
|
Arbutus Presents Clinical Trial Data from its Two HBV Assets, Imdusiran and AB-101, at the European Association for the Study of the Liver (EASL) Congress 2025
|
|
Jan 16
|
Jim Cramer on Arbutus Biopharma Corporation (ABUS): ‘It Loses Money’
|
|
Jan 15
|
Kymera Therapeutics (KYMR) Moves 7.8% Higher: Will This Strength Last?
|
|
Oct 1
|
Arbutus to Present at H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference
|
|
Aug 1
|
Arbutus Biopharma (ABUS) Reports Q2 Loss, Tops Revenue Estimates
|
|
Aug 1
|
Arbutus: Q2 Earnings Snapshot
|
|
Aug 1
|
Arbutus Reports Second Quarter 2024 Financial Results and Provides Corporate Update
|
|
Jun 13
|
Ultragenyx (RARE) Moves 7.8% Higher: Will This Strength Last?
|
|
Jun 5
|
Arbutus’ Imdusiran with Short Course Interferon Achieves Sustained Undetectable HBsAg, a Necessity for HBV Functional Cure
|
|
May 3
|
Arbutus Biopharma Corporation (NASDAQ:ABUS) Q1 2024 Earnings Call Transcript
|
|
May 3
|
Arbutus Biopharma First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
|
|
May 3
|
Arbutus Biopharma Corp (ABUS) Q1 2024 Earnings Call Transcript Highlights: Strategic ...
|
|
May 2
|
Arbutus Biopharma Corp Reports Q1 2024 Earnings: A Detailed Financial Review
|
|
May 2
|
Arbutus Biopharma (ABUS) Reports Q1 Loss, Misses Revenue Estimates
|
|
May 2
|
Arbutus Reports First Quarter 2024 Financial Results and Provides Corporate Update
|